Detailed Narrative
Strong Q3 and 9M FY26 Financial Performance
Anlon Healthcare Limited delivered robust financial results for Q3 FY26, with Total Income surging by 281.45% YoY to ₹35.78 crore, up from ₹9.38 crore in Q3 FY25. This growth was primarily fueled by higher API and intermediate volumes. The company achieved a PAT of ₹5.15 crore in Q3 FY26, a significant turnaround from a loss in the corresponding period last year. For the nine months ended FY26, Total Income increased by 69.7% YoY to ₹121.32 crore, and PAT grew to ₹18.02 crore, demonstrating strong operational scale-up.
Sustainable Margins and Future Outlook
The EBITDA margin for Q3 FY26 stood at 35.06%. Management expressed confidence in maintaining a sustainable EBITDA margin of 35% for its domestic operations and targeting at least 50% for regulated markets over the next 2-3 years. Factoring in the slightly lower margins of the acquired Apiqo Organic, the consolidated EBITDA margin is projected to remain consistently between 30-33%. The company aims for approximately 30% Revenue CAGR over the next three years, with FY27 revenue guidance of ₹370-380 crore, which is considered conservative.
Strategic Acquisitions and Capacity Expansion
The period marks a pivotal phase in Anlon's growth journey, driven by strategic inorganic and organic initiatives. The acquisition of Apiqo Organic has been completed, enhancing backward integration and adding substantial capacity. The proposed acquisition of Bizotic Life Science is expected to be finalized within three months, further accelerating expansion and regulatory readiness. Both Apiqo and Bizotic are planned to become 100% subsidiaries in FY27 via a share swap, avoiding cash outflow. Combined installed capacity is expected to reach 400-600 metric tons per annum, with significant greenfield expansion plans to add 800-1000 metric tons.
Working Capital Improvement and Funding Strategy
Currently, the company faces high working capital receivable days, approximately 290 days. Management is actively working to reduce this to 180-185 days by FY26 end and further to 150-160 days by FY27 through revised customer payment terms. Anlon anticipates generating positive operating cash flow in FY27, with at least ₹40-50 crore from routine cash flow. A planned greenfield CapEx of ₹100-120 crore will be funded through internal accruals (₹40-50 crore) and bank loans (₹50-60 crore), targeting a conservative debt-to-equity ratio of 0.5-0.55.
Product Pipeline and Diversification Efforts
Anlon has a robust product pipeline with 21 DMF filings, expecting 6-7 key molecules to be commercialized in FY27. While loxoprofen and its intermediates (NSAIDs) currently contribute 25-30% of FY27 revenue, the company is actively diversifying its therapeutic portfolio. New products are being developed for cardiac, arthritis, uncontrolled urination, chronic kidney disease, and nutraceuticals, aiming for a 10-15% contribution from these segments to de-risk the current product range.
Greenfield Expansion Timeline and AI Vision
The company is targeting an aggressive timeline for its greenfield expansion, aiming for completion within 1 year, significantly faster than the industry standard of 18-20 months, due to existing regulatory approvals. Execution is planned to commence from April 1, 2026, with completion by March 31, 2027. Additionally, management shared a long-term vision to integrate AI into healthcare, focusing on distribution, patient engagement, and drug discovery, restarting a project initially conceived in 2014-15.